

YALE SCHOOL OF MEDICINE

# PATHOLOGY

## GRAND ROUNDS AND DIAGNOSTIC SLIDE SEMINAR

Host: David Stern, PhD



**Kurt Alex Schalper, MD, PhD**

Assistant Professor of Pathology and Medicine, Department of Pathology; Director Translational Immuno-Oncology Lab, YCC Co-Director Yale SPORE Lung Cancer & Thoracic Biospecimen Resources, Yale School of Medicine

**GRAND ROUNDS: 12:30 PM**

**“Novel tumor and immune signals to guide optimal anti-cancer immunotherapy”**

**Thursday, November 12, 2020**

Zoom Meetings ID and Password: emailed separately

For information contact : [susana.cruz@yale.edu](mailto:susana.cruz@yale.edu)

*There is no corporate or grant support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.*

#### ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### TARGET AUDIENCE

Attending physicians, researchers, house staff, fellows, residents, medical students, nurses.

#### NEEDS ASSESSMENT

Anti-cancer immunotherapies have been approved to treat multiple tumor types. However, diagnostics and biomarkers to guide treatment decisions are limited. Development of additional treatment modalities targeting novel pathways is required to move the field forward.

#### LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Understand the current role of immune checkpoint blockers to treat cancer with focus on-small cell lung cancer (NSCLC).
- Analyze the value and limitations of current biomarkers for prediction of response to immunostimulatory therapy.
- Explore novel immunoregulatory pathways with diagnostic and therapeutic potential.

#### DESIGNATION STATEMENT

The Yale School of Medicine designates this live ac-

tivity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity

#### FACULTY DISCLOSURES

Speaker Name: Kurt A. Schalper MD, PhD - Shattuck labs, Pierre-Fabre, Astra Zeneca, EMD Serono, Ono Pharmaceuticals, Clinica Alemana de Santiago, Dynamo Therapeutics, Abbvie, Takeda/Millennium Pharmaceuticals, Merck, Bristol Myers-Squibb, Agenus; Torque Therapeutics, Genoptix/Navigate (Novartis), Tesaro Inc, Moderna Therapeutics, Surface Oncology, Pierre Fabre Research Institute, Ribon Therapeutics, Genetech and Eli Lilly, Fluidigm, PeerView

Course Directors: Manju Prasad, MD - NONE

Gopal Pallavi, MD, PhD - NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.